January 10, 2017: On Tuesday January 10, 2017 at 2pm Aegle will present at the 9th Annual Biotech Showcase™ 2017 being held at the Hilton San Francisco Union Square, California.




December 2016: Aegle files an IND with the FDA for the treatment of chronic pressure ulcers using allogeneic extracellular vesicles.




November 2016: Aegle files an IND with the FDA for the treatment of burns/scarring using autologous extracellular vesicles.




March 2016: Aegle Therapeutics selected for Springboard’s 2016 Health Innovation Hub.




February 2015: Aegle Therapeutics signs an exclusive license from the University of Miami (Miami, FL) for the rights to extracellular vesicle isolation technology and the use of extracellular vesicles isolated using the proprietary process for therapeutic and diagnostic indications.




April 2015: Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Virto published in Stem Cells and Development by Shabbir, A., Cox, A., Rodriguez-Menocal, L., Salgado, M. and Badiavas, E.